Phenytoin Injectable

Generic Name: Phenytoin

Brand Names:

Availability: Available with Prescription

Drug Class: Anticonvulsants

Therapeutic action

  • Anticonvulsant

Indications

  • Emergency treatment of convulsive status epilepticus

Forms and strengths, route of administration

  • 250 mg in 5 ml ampoule (50 mg/ml) for infusion in 0.9% sodium chloride DO NOT DILUTE IN GLUCOSE.
  • DO NOT ADMINISTER BY IM INJECTION.

Dosage and duration

  • Child 1 month and over and adult: one dose of 15 to 20 mg/kg to be administered over 20 minutes minimum and 60 minutes maximum
  • The concentration of the diluted solution should be between 5 and 10 mg/ml. The infusion rate should not exceed 1 mg/kg/minute or 50 mg/minute(25 mg/minute in elderly patients or patients with cardiac disorders).
  • For example:
    • Child weighing8 kg: 160 mg (20 mg x 8 kg), i.e. 3.2 ml of phenytoinin 17 ml of 0.9% sodium chloride over 30 minutes
    • Adult weighing 50 kg: 1 g (20 mg x 50 kg), i.e. 20 ml of phenytoin in a bag of 100 ml of0.9% sodium chloride over 30 minutes

Contra-indications, adverse effects, precautions

  • Do not administer in patients with bradycardia, atrioventricular block.
  • Administer with caution in patients with hepatic impairment (reduce dosage), heart failure, cardiac rhythm disorders, hypotension.
  • Administer with caution in patients taking:
    • sulfonamides, chloramphenicol, fluconazole, isoniazid, fluoxetine (effects of phenytoin increased);
    • rifampicin , ciprofloxacin, ritonavir, folic acid (effects of phenytoin decreased).
  • May cause:
    • hypotension, bradycardia, conduction disorders, depression of the central nervous system when administered too quickly;
    • irritation or swelling at injection site; necrosis in the event of extravasation; 
    • decreased coordination, confusion, dizziness, headache, nausea,vomiting;
    • hepatotoxicity; haematologic disorders; allergic and cutaneous reactions, sometimes severe.
  • Use a large catheter.
  • Monitor closely heart rate, blood pressure and respiratory rate during and after administration. Reduce the infusion rate in the event of a drop in blood pressure or bradycardia.
  • For women taking estroprogestogen, use condoms until next menstruation (decreases the efficacy of the contraceptive).
  • Pregnancy and breast-feeding: risks related to status epilepticus are greater than risks related to phenytoin.

Remarks

  • Never dilute phenytoin in glucose (risk of precipitation).
  • After each infusion, rinse with 0.9% sodium chloride to limit local venous irritation due to alkaline pH of phenytoin.
  • Do not mix with other drugs in the same infusion.

Storage

– Below 25 °C

If refrigerated a deposit may form in the solution that later dissolves at room temperature. Check the solution is completely clear before administration.